| Trial ID: | L4610 |
| Source ID: | NCT05694741
|
| Associated Drug: |
Azd0186
|
| Title: |
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: AZD0186|DRUG: Placebo
|
| Outcome Measures: |
Primary: Adverse Events (AEs), and Serious Adverse Events (SAEs), The safety and tolerability of AZD0186 following oral single ascending doses in healthy subjects (Part 1 and Part 4), in healthy Japanese subjects (Part 2), and in healthy Chinese subjects (Part 3) will be assessed., Up to the Follow-up Visit (approximately 6 weeks) | Secondary: Area under plasma concentration-time curve from zero to infinity (AUCinf), The AUCinf of AZD0186 following oral single ascending doses will be characterized., Day 1 to Day 3|Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUClast), The AUClast of AZD0186 following oral single ascending doses will be characterized., Day 1 to Day 3|Maximum observed concentration (Cmax), The Cmax of AZD0186 following oral single ascending doses will be characterized., Day 1 to Day 3
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Parexel
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-12-20
|
| Completion Date: |
2023-05-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-13
|
| Locations: |
Research Site, Glendale, California, 91206, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05694741
|
